triumeq film coated tablet 50mg600mg300mg
glaxosmithkline pte ltd - abacavir sulfate 702.0mg eqv abacavir; dolutegravir sodium 52.6mg eqv dolutegravir; lamivudine - tablet, film coated - abacavir sulfate 702.0mg eqv abacavir 600 mg; dolutegravir sodium 52.6mg eqv dolutegravir 50 mg; lamivudine 300 mg
viropil tablets film-coated
emcure pharmaceuticals ltd. - dolutegravir (dolutegravir sodium), lamivudine, tenofovir disoproxil fumarate - tablets film-coated - 50mg+ 300mg+ 300mg
avonza tablets film-coated
mylan laboraories limited - tenofovir disoproxil fumarate, lamivudine,efavirenz - tablets film-coated - 300mg+ 300mg+ 400mg
amcal+ ibuprofen sodium dihydrate 256 mg film coated tablet blister pack
neo health (otc) pty ltd - ibuprofen sodium dihydrate, quantity: 256 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; xylitol; titanium dioxide; hypromellose; macrogol 400 - temporary relief of pain (and discomfort) associated with headache, migraine headache, tension headache, sinus pain, toothache, dental procedures,,backache, muscular aches and pains, period pain, sore throat, arthritis, rheumatic pain where inflammation is present, and the aches and pains,associated with colds and flu. reduces fever.
lamivudine/zidovudine viatris 150/300
viatris limited - lamivudine 150mg; zidovudine 300mg - film coated tablet - active: lamivudine 150mg zidovudine 300mg excipient: colloidal silicon dioxide magnesium stearate microcrystalline cellulose opadry white propylene glycol purified water sodium starch glycolate - indicated for the treatment of hiv infected adults and adolescents over the age of 12 years, with progressive immunodeficiency (cd4+ count = < 500 cells/mm³).
kivexa
glaxo smith kline (israel) ltd - abacavir as sulfate; lamivudine - film coated tablets - abacavir as sulfate 600 mg; lamivudine 300 mg - nucleoside and nucleotide reverse transcriptase inhibitors - kivexa is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults, adolescents and children weighing at least 25 kg.
imatinib rbx imatinib (as mesilate) 400 mg tablet blister pack
sun pharma anz pty ltd - imatinib mesilate, quantity: 478 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red - imatinib rbx is indicated for the: ? treatment of patients with chronic myeloid leukaemia (cml) ? treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy ? treatment of adult patients with relapsed or refractory ph+ all as monotherapy ? treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements, where conventional therapies have failed ? treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed ? treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) ? treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) ? adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist (see dosage and administration and clinical trials) ? treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp).
imatinib rbx imatinib (as mesilate) 100 mg tablet bottle pack
sun pharma anz pty ltd - imatinib mesilate, quantity: 119.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red - imatinib rbx is indicated for the: ? treatment of patients with chronic myeloid leukaemia (cml) ? treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy ? treatment of adult patients with relapsed or refractory ph+ all as monotherapy ? treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements, where conventional therapies have failed ? treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed ? treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) ? treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) ? adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist (see dosage and administration and clinical trials) ? treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp).
imatinib rbx imatinib (as mesilate) 100 mg tablet blister pack
sun pharma anz pty ltd - imatinib mesilate, quantity: 119.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red - imatinib rbx is indicated for the: ? treatment of patients with chronic myeloid leukaemia (cml) ? treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy ? treatment of adult patients with relapsed or refractory ph+ all as monotherapy ? treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements, where conventional therapies have failed ? treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed ? treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) ? treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) ? adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist (see dosage and administration and clinical trials) ? treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp).
imatinib rbx imatinib (as mesilate) 400 mg tablet bottle pack
sun pharma anz pty ltd - imatinib mesilate, quantity: 478 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red - imatinib rbx is indicated for the: ? treatment of patients with chronic myeloid leukaemia (cml) ? treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy ? treatment of adult patients with relapsed or refractory ph+ all as monotherapy ? treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements, where conventional therapies have failed ? treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed ? treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) ? treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) ? adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist (see dosage and administration and clinical trials) ? treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp).